youtube_live
Q1 2026: ΠΏΡΠΈΠ±ΡΠ»Ρ β’ ΡΠ΅ΡΠ΅Π· 3 Π΄Π½.
ΠΠΎΠ΄ΡΠΎΠ±Π½Π΅Π΅chevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
24,77Β $
arrow_upward
+0,32%(+0,080) 1Π
24,69Β $
arrow_downward
-0,32% (-0,080)bedtimeΠΠΎΡΠ»Π΅ Π·Π°ΠΊΡΡΡΠΈΡ ΡΠ΅ΡΡΠΈΠΈ
Π’ΠΎΡΠ³ΠΈ Π·Π°ΠΊΡΡΡΡ: 1 ΠΌΠ°Ρ, 16:00:00 GMT-4 · USD
search
ΠΡΠ΅ ΡΠΈΠΌΠ²ΠΎΠ»Ρ
1Π
5ΠΠ
1ΠΠΠ‘
6ΠΠΠ‘
Π‘1Π―Π
1ΠΠΠ
5ΠΠΠ’
ΠΠΠΠ‘
| Π‘ΠΈΠΌΠ²ΠΎΠ» | Π¦Π΅Π½Π° | ΠΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ | ΠΠΈΠ½Π°ΠΌΠΈΠΊΠ° (%) |
|---|
insights_autoΠ‘ΠΎΠ·Π΄Π°Π½ΠΈΠ΅ ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠΈ Π΄Π»Ρ ΡΠΈΠΊΠ΅ΡΠ° RAREβ¦
ΠΡΠΊΡΡΡΡ
24,90Β $
ΠΡΡΠΎΠΊΠ°Ρ
25,12Β $
ΠΠΈΠ·ΠΊΠ°Ρ
24,36Β $
Π ΡΠ½. ΠΊΠ°ΠΏ.
2,44Β ΠΌΠ»ΡΠ΄
Π‘ΡΠ΅Π΄Π½. ΠΎΠ±ΡΠ΅ΠΌ
2,04Β ΠΌΠ»Π½
ΠΠ±ΡΠ΅ΠΌ
1,41Β ΠΌΠ»Π½
ΠΠ°ΠΊΡ. ΡΠ΅Π½Π° Π·Π° 52 Π½Π΅Π΄.
42,37Β $
ΠΠΈΠ½. ΡΠ΅Π½Π° Π·Π° 52 Π½Π΅Π΄.
18,29Β $
ΠΡΠΈΠ±ΡΠ»Ρ Π½Π° Π°ΠΊΡΠΈΡ
-5,83Β $
ΠΠ΅ΡΠ°
0,25
ΠΠΊΡΠΈΠΈ Π² ΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠΈ
98,32Β ΠΌΠ»Π½
Π§ΠΈΡΠ»ΠΎ ΡΠΎΡΡΡΠ΄Π½ΠΈΠΊΠΎΠ²
1Β ΡΡΡ.
ΠΠΎΠ²ΠΎΡΡΠΈ
ΠΠ· ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ² Π² ΠΈΠ½ΡΠ΅ΡΠ½Π΅ΡΠ΅
MoneyWise.com
·
35 ΠΌΠΈΠ½ΡΡ Π½Π°Π·Π°Π΄
Goldman Sachs warns S&P 500's record highs are built on 'froth' β and a sell-off could hit your portfolio next
Simply Wall Street
·
51 ΠΌΠΈΠ½ΡΡΡ Π½Π°Π·Π°Π΄
Wingstop Weighs AI Loyalty Push India Entry And Smart Kitchen Gains
MarketBeat
·
1 ΡΠ°Ρ Π½Π°Π·Π°Π΄
NextDecade (NASDAQ:NEXT) Announces Earnings Results, Beats Expectations By $0.15 EPS
Investor's Business Daily
·
1 ΡΠ°Ρ Π½Π°Π·Π°Π΄
Dow Jones Futures: Stock Market Hits High After Bullish Pause; Apple, Broadcom In Buy Zones
ΠΡΠΎΡΠΈΠ»Ρ
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The companyβs Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneronβs evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Π ΠΊΠΎΠΌΠΏΠ°Π½ΠΈΠΈ "Ultragenyx Pharmaceutical Inc"
ΠΠ΅Π½Π΅ΡΠ°Π»ΡΠ½ΡΠΉ Π΄ΠΈΡΠ΅ΠΊΡΠΎΡΠΠΌΠΈΠ»Ρ ΠΠ°ΠΊΠΊΠΈΡ
ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΡΠΎΡΡΡΠ΄Π½ΠΈΠΊΠΎΠ²1,37Β ΡΡΡ.
ΠΠ°ΡΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΡ2010
Π¨ΡΠ°Π±-ΠΊΠ²Π°ΡΡΠΈΡΠ°ΠΠΎΠ²Π°ΡΠΎ, ΠΠ°Π»ΠΈΡΠΎΡΠ½ΠΈΡ, Π‘ΠΎΠ΅Π΄ΠΈΠ½Π΅Π½Π½ΡΠ΅ Π¨ΡΠ°ΡΡ ΠΠΌΠ΅ΡΠΈΠΊΠΈ
Π‘Π΅ΠΊΡΠΎΡ-
Π‘Π°ΠΉΡultragenyx.com
Π‘ΠΎΠ·Π΄Π°Π½Π½ΡΠΉ ΠΠ ΠΊΠΎΠ½ΡΠ΅Π½Ρ ΠΌΠΎΠΆΠ΅Ρ ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΡ ΠΎΡΠΈΠ±ΠΊΠΈ. ΠΠΎΠ΄ΡΠΎΠ±Π½Π΅Π΅β¦
Π‘ΠΏΡΠ°Π²ΠΊΠ°ΠΡΠΏΡΠ°Π²ΠΈΡΡ ΠΎΡΠ·ΡΠ²ΠΠΎΠ½ΡΠΈΠ΄Π΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΡΡΡΠ£ΡΠ»ΠΎΠ²ΠΈΡΠΡΠΊΠ°Π· ΠΎΡ ΠΎΠ±ΡΠ·Π°ΡΠ΅Π»ΡΡΡΠ²